Complex DNA repair pathways as possible therapeutic targets to overcome temozolomide resistance in glioblastoma
Open accessAbstract
Many conventional chemotherapeutic drugs exert their cytotoxic function by inducing DNA damage in the tumor cell. Therefore, a cell-inherent DNA repair pathway, which reverses the DNA-damaging effect of the cytotoxic drugs, can mediate therapeutic resistance to chemotherapy. The monofunctional DNA-alkylating agent temozolomide (TMZ) is a commonly used chemotherapeutic drug and the gold standard treatment for glioblastoma (GBM). Although the activity of DNA repair protein O6-methylguanine-DNA methyltransferase (MGMT) has been described as the main modulator to determine the sensitivity of GBM to TMZ, a subset of GBM does not respond despite MGMT inactivation, suggesting that another DNA repair mechanism may also modulate the tolerance to TMZ. Considerable interest has focused on MGMT, mismatch repair (MMR), and the base excision repair (BER) pathway in the mechanism of mediating TMZ resistance, but emerging roles for the DNA strand-break repair pathway have been demonstrated. In the first part of this review article, we briefly review the significant role of MGMT, MMR, and the BER pathway in the tolerance to TMZ; in the last part, we review the recent publications that demonstrate possible roles of DNA strand-break repair pathways, such as single-strand break repair and double-strand break repair, as well as the Fanconi anemia pathway in the repair process after alkylating agent-based therapy. It is possible that all of these repair pathways have a potential to modulate the sensitivity to TMZ and aid in overcoming the therapeutic resistance in the clinic.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
APE1 and MGMT can be expressed at high levels in GBM and are major predictors of TMZ resistance.
“The DNA repair proteins APE1 and MGMT can be expressed at high levels in GBM and are major predictors of TMZ resistance.49”
From Combination therapy in a xenograft model of glioblastoma: Enhancement of the antitumor activity of temozolomide by an MDM2 antagonist (2017) · cites this paper as [49]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
The Cancer Genome Atlas Research Network (2008) · Nature · doi:10.1038/nature07385 · Cited by 7,735 · see citing works
Stupp, R., Hegi, M. E., Mason, W. P., van den Bent, M. J., TAPHOORN, M. J. B., Janzer, R. C., Ludwin, S. K., Allgeier, A., Fisher, B., Bélanger, K., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70025-7 · Cited by 7,667 · see citing works
<i>MGMT</i> Gene Silencing and Benefit from Temozolomide in Glioblastoma
Hegi, M. E., Diserens, A.-C., Gorlia, T., Hamou, M.-F., de Tribolet, N., Weller, M., Kros, J. M., Hainfellner, J. A., Mason, W., Mariani, L., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043331 · Cited by 7,405 · see citing works
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683 · see citing works
The DNA-damage response in human biology and disease
Jackson, S. P., & Bartek, J. (2009) · Nature · doi:10.1038/nature08467 · Cited by 6,092 · see citing works
An Integrated Genomic Analysis of Human Glioblastoma Multiforme
Parsons, D. W., Jones, S., Zhang, X., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Siu, I.-M., Gallia, G. L., et al. (2008) · Science · doi:10.1126/science.1164382 · Cited by 5,857 · see citing works
The DNA Damage Response: Making It Safe to Play with Knives
Ciccia, A., & Elledge, S. J. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.09.019 · Cited by 4,368 · see citing works
Wen, P. Y., & Kesari, S. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0708126 · Cited by 4,201 · see citing works
Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from <i>BRCA</i> Mutation Carriers
Fong, P. C., Boss, D. S., Yap, T. A., Tutt, A., Wu, P., Mergui-Roelvink, M., Mortimer, P., Swaisland, H., Lau, A., O'Connor, M. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0900212 · Cited by 3,634 · see citing works
Poly(ADP-ribose): novel functions for an old molecule
Schreiber, V., Dantzer, F., Amé, J., & de MURCIA, G. (2006) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1963 · Cited by 1,917 · see citing works
The DNA damage response and cancer therapy
Lord, C. J., & Ashworth, A. (2012) · Nature · doi:10.1038/nature10760 · Cited by 1,843 · see citing works
ATR: an essential regulator of genome integrity
Cimprich, K. A., & Cortez, D. (2008) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2450 · Cited by 1,798 · see citing works
The DNA Damage Response: Ten Years After
Harper, J. W., & Elledge, S. J. (2007) · Molecular Cell · doi:10.1016/j.molcel.2007.11.015 · Cited by 1,705 · see citing works
DNA repair pathways as targets for cancer therapy
Helleday, T., Petermann, E., Lundin, C., Hodgson, B., & Sharma, R. A. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2342 · Cited by 1,666 · see citing works
BRCA1 and BRCA2: different roles in a common pathway of genome protection
Roy, R., Chun, J., & Powell, S. N. (2011) · Nature reviews. Cancer · doi:10.1038/nrc3181 · Cited by 1,479 · see citing works
Essential role for nuclear PTEN in maintaining chromosomal integrity
Shen, W. H., Balajee, A. S., Wang, J., Wu, H., Eng, C., Pandolfi, P. P., & Yin, Y. (2007) · Cell · doi:10.1016/j.cell.2006.11.042 · Cited by 979 · see citing works
Balancing repair and tolerance of DNA damage caused by alkylating agents
Fu, D., Calvo, J. A., & Samson, L. D. (2012) · Nature reviews. Cancer · doi:10.1038/nrc3185 · Cited by 946 · see citing works
DNA damage-induced cell death: From specific DNA lesions to the DNA damage response and apoptosis
Roos, W. P., & Kaina, B. (2013) · Cancer Letters · doi:10.1016/j.canlet.2012.01.007 · Cited by 879 · see citing works
The Fanconi anaemia/BRCA pathway
D'Andrea, A. D., & Grompe, M. (2003) · Nature Reviews Cancer · doi:10.1038/nrc970 · Cited by 822 · see citing works
MGMT: its role in cancer aetiology and cancer therapeutics
Gerson, S. L. (2004) · Nature reviews. Cancer · doi:10.1038/nrc1319 · Cited by 817 · see citing works
Hegi, M. E., Liu, L., Herman, J. G., Stupp, R., Wick, W., Weller, M., Mehta, M. P., & Gilbert, M. R. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.5964 · Cited by 811 · see citing works
Poly(ADP-ribosyl)ation by PARP-1: `PAR-laying' NAD + into a nuclear signalPreprint
Kim, M. Y., Zhang, T., & Kraus, W. L. (2005) · Genes & Development · doi:10.1101/gad.1331805 · Cited by 803 · see citing works
Pegg, A. E. (1990) · PubMed · Cited by 734 · see citing works
On PAR with PARP: cellular stress signaling through poly(ADP-ribose) and PARP-1Preprint
Luo, X., & Kraus, W. L. (2012) · Genes & Development · doi:10.1101/gad.183509.111 · Cited by 725 · see citing works
Temozolomide and treatment of malignant glioma.
Friedman, H. S., Kerby, T., & Calvert, H. (2000) · PubMed · Cited by 722 · see citing works
DNA double-strand break repair: From mechanistic understanding to cancer treatment
HELLEDAY, T., LO, J., VANGENT, D., & ENGELWARD, B. (2007) · DNA Repair · doi:10.1016/j.dnarep.2007.02.006 · Cited by 640 · see citing works
Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors
Mendes‐Pereira, A. M., Martin, S. A., Brough, R., McCarthy, A., Taylor, J. R., Kim, J., Waldman, T. A., Lord, C. J., & Ashworth, A. (2009) · EMBO Molecular Medicine · doi:10.1002/emmm.200900041 · Cited by 630 · see citing works
The effects of deregulated DNA damage signalling on cancer chemotherapy response and resistance
Bouwman, P., & Jonkers, J. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3342 · Cited by 615 · see citing works
Regulation of DNA cross-link repair by the Fanconi anemia/BRCA pathwayPreprint
Kim, H., & D’Andrea, A. D. (2012) · Genes & Development · doi:10.1101/gad.195248.112 · Cited by 510 · see citing works
Roos, W. P., Batista, L. F. Z., Naumann, S. C., Wick, W., Weller, M., Menck, C. F. M., & Kaina, B. (2006) · Oncogene · doi:10.1038/sj.onc.1209785 · Cited by 499 · see citing works
The diverse roles and clinical relevance of PARPs in DNA damage repair: Current state of the art
Vos, M. D., Schreiber, V., & Dantzer, F. (2012) · Biochemical Pharmacology · doi:10.1016/j.bcp.2012.03.018 · Cited by 491 · see citing works
Calabrese, C. R., Almassy, R., Barton, S., Batey, M. A., Calvert, A. H., Canan-Koch, S., Durkacz, B. W., Hostomsky, Z., Kumpf, R. A., Kyle, S., et al. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh005 · Cited by 487 · see citing works
MGMT Gene Silencing and Benefit From Temozolomide in Glioblastoma
Verma, A. (2006) · Yearbook of Neurology and Neurosurgery · doi:10.1016/s0513-5117(08)70328-4 · Cited by 467 · see citing works
The role of DNA mismatch repair in drug resistance
Nebel, S. (1998) · ETH Zürich Research Collection · doi:10.3929/ethz-a-001915508 · Cited by 465 · see citing works
Cahill, D. P., Levine, K. K., Betensky, R. A., Codd, P. J., Romany, C. A., Reavie, L. B., Batchelor, T. T., Futreal, P. A., Stratton, M. R., Curry, W. T., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2149 · Cited by 450 · see citing works
Almeida, K. H., & Sobol, R. W. (2007) · DNA Repair · doi:10.1016/j.dnarep.2007.01.009 · Cited by 437 · see citing works
Hunter, C., Smith, R., Cahill, D. P., Stephens, P., Stevens, C., Teague, J. W., Greenman, C., Edkins, S., Bignell, G. R., Davies, H. R., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0127 · Cited by 431 · see citing works
DNA glycosylases: In DNA repair and beyond
Jacobs, A. L., & Schär, P. (2012) · Chromosoma · doi:10.1007/s00412-011-0347-4 · Cited by 407 · see citing works
Yip, S. S. F., Miao, J., Cahill, D. P., Iafrate, A. J., Aldape, K., Nutt, C. L., & Louis, D. N. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-3012 · Cited by 403 · see citing works
Mismatch repair and DNA damage signalling
Stojic, L., Brun, R., & Jiricny, J. (2004) · DNA Repair · doi:10.1016/j.dnarep.2004.06.006 · Cited by 396 · see citing works
van der Burgt, I., Chrzańowska, K., Smeets, D. F. C. M., & Weemaes, C. (1996) · Journal of Medical Genetics · doi:10.1136/jmg.33.2.153 · Cited by 377 · see citing works
Mechanisms of Chemoresistance to Alkylating Agents in Malignant Glioma
Sarkaria, J. N., Kitange, G. J., James, C. D., Plummer, R., Calvert, H., Weller, M., & Wick, W. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1719 · Cited by 373 · see citing works
Changing Paradigms—An Update on the Multidisciplinary Management of Malignant Glioma
Stupp, R., Hegi, M. E., van den Bent, M. J., Mason, W. P., Weller, M., Mirimanoff, R. O., & Cairncross, J. G. (2006) · The Oncologist · doi:10.1634/theoncologist.11-2-165 · Cited by 372 · see citing works
FORTINI, P., & DOGLIOTTI, E. (2007) · DNA Repair · doi:10.1016/j.dnarep.2006.10.008 · Cited by 318 · see citing works
Quinn, J. A., Jiang, X. “., Reardon, D. A., Desjardins, A., Vredenburgh, J. J., Rich, J. N., Gururangan, S., Friedman, A. H., Bigner, D. D., Sampson, J. H., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.8417 · Cited by 314 · see citing works
Expanded roles of the Fanconi anemia pathway in preserving genomic stabilityPreprint
Kee, Y., & D’Andrea, A. D. (2010) · Genes & Development · doi:10.1101/gad.1955310 · Cited by 309 · see citing works
Recent Advances in the Treatment of Malignant Astrocytoma
Reardon, D. A., Rich, J. N., Friedman, H. S., & Bigner, D. D. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.5302 · Cited by 308 · see citing works
DNA Damage Induced by Alkylating Agents and Repair Pathways
Kondo, N., Takahashi, A., Ono, K., & Ohnishi, T. (2010) · Journal of Nucleic Acids · doi:10.4061/2010/543531 · Cited by 299 · see citing works
Felsberg, J., Thon, N., Eigenbrod, S., Hentschel, B., Sabel, M., Westphal, M., Schackert, G., Kreth, F. W., Pietsch, T., Löffler, M., et al. (2011) · International Journal of Cancer · doi:10.1002/ijc.26083 · Cited by 298 · see citing works
ATR: a master conductor of cellular responses to DNA replication stress
Flynn, R. L., & Zou, L. (2011) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2010.09.005 · Cited by 290 · see citing works
Homologous recombination in cancer development, treatment and development of drug resistance
Helleday, T. (2010) · Carcinogenesis · doi:10.1093/carcin/bgq064 · Cited by 288 · see citing works
Involvement of the Mismatch Repair System in Temozolomide-Induced Apoptosis
D’Atri, S., Tentori, L., Lacal, P. M., Graziani, G., Pagani, E., Benincasa, E., Zambruno, G., Bonmassar, E., & Jiricny, J. (1998) · Molecular Pharmacology · doi:10.1124/mol.54.2.334 · Cited by 282 · see citing works
The role of poly(ADP-ribose) in the DNA damage signaling network
Malanga, M., & Althaus, F. R. (2005) · Biochemistry and Cell Biology · doi:10.1139/o05-038 · Cited by 274 · see citing works
Armah, H. B. (2010) · Yearbook of Pathology and Laboratory Medicine · doi:10.1016/s1077-9108(09)79430-7 · Cited by 271 · see citing works
Mukherjee, B., Mcellin, B. M., Camacho, C. V., Tomimatsu, N., Sirasanagandala, S., Nannepaga, S., Hatanpaa, K. J., Mickey, B., Madden, C. J., Maher, E. A., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4853 · Cited by 269 · see citing works
Harnessing synthetic lethal interactions in anticancer drug discovery
Chan, D. A., & Giaccia, A. J. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3374 · Cited by 260 · see citing works
Base Excision Repair and Lesion-Dependent Subpathways for Repair of Oxidative DNA Damage
Svilar, D., Goellner, E. M., Almeida, K. H., & Sobol, R. (2011) · Antioxidants and Redox Signaling · doi:10.1089/ars.2010.3466 · Cited by 254 · see citing works
Stojic, L., Mojas, N., Cejka, P., di Pietro, M., Ferrari, S., Marra, G., & Jiricny, J. (2004) · Genes & Development · doi:10.1101/gad.294404 · Cited by 246 · see citing works
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
Uhm, J. H. (2009) · Yearbook of Neurology and Neurosurgery · doi:10.1016/s0513-5117(09)79089-1 · Cited by 244 · see citing works
Trivedi, R. N., Almeida, K. H., Fornsaglio, J. L., Schamus, S., & Sobol, R. W. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0715 · Cited by 242 · see citing works
Mcellin, B. M., Camacho, C. V., Mukherjee, B., Hahm, B., Tomimatsu, N., Bachoo, R. M., & Burma, S. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-4295 · Cited by 230 · see citing works
The role of DNA mismatch repair in drug resistance.
Fink, D. A., Aebi, S. P., & Howell, S. B. (1998) · PubMed · Cited by 220 · see citing works
Tentori, L., Leonetti, C., Scarsella, M., d’Amati, G., Vergati, M., Portarena, I., Xu, W., Kalish, V. J., Zupi, G., Zhang, J., et al. (2003) · PubMed · Cited by 204 · see citing works
A Novel Methionine-Based Signaling Mechanism Regulating the Expression of Thymidylate Synthase
Chu, E. (2003) · Cancer Biology & Therapy · doi:10.4161/cbt.2.4.460 · Cited by 178 · see citing works
Agnihotri, S., Gajadhar, A. S., Ternamian, C., Gorlia, T., Alfaro-Munoz, K. D., Mischel, P. S., Kelly, J. R., McGown, G., Thorncroft, M. R., Carlson, B. L., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci59334 · Cited by 172 · see citing works
Cheng, C.-M., Johnson, S. P., Keir, S. T., Quinn, J. A., Ali‐Osman, F., Szabó, C., Li, H., Salzman, A. L., Dolan, M. E., Modrich, P. L., et al. (2005) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0128 · Cited by 171 · see citing works
An Integrated Genomic Analysis of Human Glioblastoma Multiforme
Arceci, R. J. (2009) · Yearbook of Oncology · doi:10.1016/s1040-1741(09)79352-2 · Cited by 167 · see citing works
Curtin, N. J., Wang, L.-Z., Yiakouvaki, A., Kyle, S., Arris, C. A., Canan-Koch, S., Webber, S. E., Durkacz, B. W., Calvert, H., Hostomský, Z., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-1144-3 · Cited by 164 · see citing works
New (alternative) temozolomide regimens for the treatment of glioma
Wick, W., Platten, M., & Weller, M. (2008) · Neuro-Oncology · doi:10.1215/15228517-2008-078 · Cited by 163 · see citing works
Ming, M., & He, Y. (2012) · Cancer Letters · doi:10.1016/j.canlet.2012.01.003 · Cited by 146 · see citing works
Harnessing the complexity of DNA-damage response pathways to improve cancer treatment outcomes
Al‐Ejeh, F., Kumar, R., Wiegmans, A. P., Lakhani, S. R., Brown, M. P., & Khanna, K. K. (2010) · Oncogene · doi:10.1038/onc.2010.407 · Cited by 139 · see citing works
Methylator resistance mediated by mismatch repair deficiency in a glioblastoma multiforme xenograft.
Friedman, H. S., Johnson, S. P., Dong, Q. D., et al. (1997) · PubMed · Cited by 133 · see citing works
DNA Damage Induced by Temozolomide Signals to both ATM and ATR: Role of the Mismatch Repair System
Caporali, S., Falcinelli, S., Starace, G., Russo, M. T., Bonmassar, E., Jiricny, J., & D’Atri, S. (2004) · Molecular Pharmacology · doi:10.1016/s0026-895x(24)05630-x · Cited by 131 · see citing works
DNA Repair: From Genome Maintenance to Biomarker and Therapeutic Target
Jalal, S. I., Earley, J. N., & Turchi, J. J. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0761 · Cited by 130 · see citing works
Löser, D. A., Shibata, A., Shibata, A., Woodbine, L. J., Jeggo, P. A., & Chalmers, A. J. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-1027 · Cited by 127 · see citing works
Emerging cancer therapeutic opportunities target DNA-repair systems
Ding, J., Miao, Z., Meng, L., & Geng, M. (2006) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2006.04.007 · Cited by 120 · see citing works
GILBERT, M. R., Wang, M., Aldape, K., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.29.15_suppl.2006 · Cited by 120 · see citing works
Exploiting synthetic lethal interactions for targeted cancer therapy
Reinhardt, H. C., Jiang, H., Hemann, M. T., & Yaffe, M. B. (2009) · Cell Cycle · doi:10.4161/cc.8.19.9626 · Cited by 110 · see citing works
Kinsella, T. J. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1307 · Cited by 105 · see citing works
Targeting DNA damage and repair: Embracing the pharmacological era for successful cancer therapy
Aziz, K., Nowsheen, S., Pantelias, G. E., Iliakis, G. E., Gorgoulis, V. G., & Georgakilas, A. G. (2011) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2011.11.010 · Cited by 104 · see citing works
Short, S. C., Giampieri, S., Worku, M., Alcaide-German, M., Sioftanos, G., Bourne, S., Lio, K. I., Shaked-Rabi, M., & Martindale, C. A. (2011) · Neuro-Oncology · doi:10.1093/neuonc/nor010 · Cited by 103 · see citing works
Synthetic lethal approaches to breast cancer therapy
Rehman, F. L., Lord, C. J., & Ashworth, A. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.172 · Cited by 102 · see citing works
Rad51 and BRCA2 - New Molecular Targets for Sensitizing Glioma Cells to Alkylating Anticancer Drugs
Quirós, S., Roos, W. P., & Kaina, B. (2011) · PLoS ONE · doi:10.1371/journal.pone.0027183 · Cited by 102 · see citing works
DNA repair inhibition: a selective tumour targeting strategy
Madhusudan, S., & Hickson, I. D. (2005) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2005.09.004 · Cited by 99 · see citing works
Dose‐dense temozolomide regimens
Neyns, B., Tosoni, A., Hwu, W., & Reardon, D. A. (2010) · Cancer · doi:10.1002/cncr.25035 · Cited by 98 · see citing works
Liu, X., Han, E. K.-H., Anderson, M. G., Shi, Y., Semizarov, D., Wang, G., McGonigal, T. P., Roberts, L., Lasko, L. M., Palma, J. P., et al. (2009) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-09-0299 · Cited by 92 · see citing works
The Fanconi anemia (FA) pathway confers glioma resistance to DNA alkylating agents
Chen, C. C., Taniguchi, T., & D’Andrea, A. D. (2007) · Journal of Molecular Medicine · doi:10.1007/s00109-006-0153-2 · Cited by 87 · see citing works
Mismatch repair proteins as sensors of alkylation DNA damage
Wang, J. Y. J., & Edelmann, W. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.05.013 · Cited by 86 · see citing works
Wedge, S. R., & Newlands, E. (1996) · British Journal of Cancer · doi:10.1038/bjc.1996.203 · Cited by 84 · see citing works
How to kill tumor cells with inhibitors of poly(ADP‐ribosyl)ation
Mangerich, A., & Bürkle, A. (2010) · International Journal of Cancer · doi:10.1002/ijc.25683 · Cited by 83 · see citing works
Key concepts in glioblastoma therapy
Bartek, J. J., Ng, K., Bartek, J. J., Fischer, W., Carter, B. S., & Chen, C. C. (2012) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2011-300709 · Cited by 72 · see citing works
Tentori, L., Portarena, I., Torino, F., Scerrati, M., Navarra, P., & Graziani, G. (2002) · Glia · doi:10.1002/glia.10113 · Cited by 66 · see citing works
Zhuang, W., Li, B.-Z., Long, L., Chen, L., Huang, Q., & Liang, Z. (2010) · Brain Research · doi:10.1016/j.brainres.2010.11.044 · Cited by 64 · see citing works
Mirzoeva, O. K., Kawaguchi, T., & Pieper, R. O. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0183 · Cited by 52 · see citing works
FANCD1/BRCA2 Plays Predominant Role in the Repair of DNA Damage Induced by ACNU or TMZ
Kondo, N., Takahashi, A., Mori, E., Noda, T., Zdzienicka, M. Z., Thompson, L. H., Helleday, T., Suzuki, M., Kinashi, Y., Masunaga, S., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0019659 · Cited by 41 · see citing works
Poly(ADP-ribosyl)ation polymerases: mechanism and new target of anticancer therapy
Heitz, F., Harter, P., Ewald-Riegler, N., Papsdorf, M., Kommoss, S., & du Bois, A. (2010) · Expert Review of Anticancer Therapy · doi:10.1586/era.10.53 · Cited by 39 · see citing works
Moss, M. A., Varvel, N. H., Nichols, M. R., Reed, D. K., & Rosenberry, T. L. (2004) · PubMed · doi:10.1124/mol.66.3 · Cited by 37 · see citing works
Chalmers, A. J. (2010) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/187152010793498627 · Cited by 37 · see citing works
Targeting DNA repair and the cell cycle in glioblastoma
Alexander, B. M., Pinnell, N. E., Wen, P. Y., & D’Andrea, A. D. (2011) · Journal of Neuro-Oncology · doi:10.1007/s11060-011-0765-4 · Cited by 36 · see citing works
Glioblastoma multiforme: the role of DSB repair between genotype and phenotype
Fischer, U., & Meese, E. U. (2007) · Oncogene · doi:10.1038/sj.onc.1210878 · Cited by 33 · see citing works
Cahill, D. P., Codd, P. J., Batchelor, T., et al. (2007) · Neurosurgery · doi:10.1227/01.neu.0000279946.20527.cd · Cited by 31 · see citing works
Targeted Therapy for Brain Tumours: Role of PARP Inhibitors
Leonetti, C., Biroccio, A., Graziani, G., & Tentori, L. (2012) · Current Cancer Drug Targets · doi:10.2174/156800912799277403 · Cited by 25 · see citing works
DNA ligase IV is a potential molecular target in ACNU sensitivity
Kondo, N., Takahashi, A., Mori, E., Noda, T., Su, X., Ohnishi, K., McKinnon, P. J., Sakaki, T., Nakase, H., Ono, K., et al. (2010) · Cancer Science · doi:10.1111/j.1349-7006.2010.01591.x · Cited by 22 · see citing works
Eich, M., Roos, W. P., Dianov, G. L., Digweed, M., & Kaina, B. (2010) · Molecular Pharmacology · doi:10.1124/mol.110.066076 · Cited by 18 · see citing works
Targeting cancer-specific synthetic lethality in double-strand DNA break repair
Moeller, B. J., Pasqualini, R., & Arap, W. (2009) · Cell Cycle · doi:10.4161/cc.8.12.8743 · Cited by 16 · see citing works
Prolonged Cell Cycle Response of HeLa Cells to Low-Level Alkylation Exposure
Schroering, A. G., Kothandapani, A., Patrick, S. M., Saravanan, K., Sharma, V. P., & Williams, K. J. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-0899 · Cited by 14 · see citing works
Agnihotri, S., Gajadhar, A. S., Ternamian, C., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci62856 · Cited by 14 · see citing works
Targeting the Molecular Defect in BRCA-Deficient Tumors for Cancer Therapy
Venkitaraman, A. R. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.07.011 · Cited by 12 · see citing works
611 Homologous recombination in cancer development, treatment and development of drug resistance
Helleday, T. (2010) · European Journal of Cancer Supplements · doi:10.1016/s1359-6349(10)71412-9 · Cited by 5 · see citing works
Flagged first, then by citations
Research works printed but not linked: 1
- Miknyoczki S. J. Jones-Bolin S. Pritchard S. Hunter K. Zhao H. Wan W. H. (2003). Chemopotentiation of temozolomide, irinotecan, and cisplatin activity by CEP-6800, a poly(ADP-ribose) polymerase inhibitor. Mol. Cancer Ther. 2 371– 382 12700281
Cited by
Sorted by citations
Genetic screens in human cells using the CRISPR-Cas9 system
Wang, T., Wei, J. J., Sabatini, D. M., & Lander, E. S. (2014) · Science · doi:10.1126/science.1246981 · Cited by 2,856 · see citing works
Wang, H., Cai, S., Bailey, B. J., Reza Saadatzadeh, M., Ding, J., Tonsing-Carter, E., Georgiadis, T. M., Zachary Gunter, T., Long, E. C., Minto, R. E., et al. (2017) · Journal of Neurosurgery · doi:10.3171/2016.1.jns152513 · Cited by 49 · see citing works
- Authors
- Yoshimoto, K., Mizoguchi, M., Hata, N., Murata, H., Hatae, R., Amano, T., Nakamizo, A., & Sasaki, T.
- Affiliations
- Kyushu University (JP)
- Corresponding author
- Yoshimoto, Koji
- Venue
- Frontiers in Oncology
- Publisher
- Frontiers Media SA
- Published
- 2012
- Volume
- 2
- Pages
- 186-186
- ISSN
- 2234-943X (ISSN-L)
- PMC
- PMC3514620
- OpenAlex
- W2088228543
- Cited by
- 126
- References
- 109
- Citations by year
- 2026: 7 · 2025: 10 · 2024: 11 · 2023: 9 · 2022: 14 · 2021: 14 · 2020: 11 · 2019: 9 · 2018: 12 · 2017: 7 · 2016: 8 · 2015: 7 · 2014: 3 · 2013: 4
- FWCI
- 1.80
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- Locations
- Frontiers in Oncology (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Ministry of Education, Culture, Sports, Science and Technology
- Japan Society for the Promotion of Science (22390280, 23659691)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › DNA Repair Mechanisms
- Health Sciences › Medicine › Genetics › Glioma Diagnosis and Treatment
- Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
- Keywords
- temozolomide resistance, glioblastoma, DNA repair pathways, O6-methylguanine-DNA methyltransferase, DNA mismatch repair, base excision repair, single-strand break repair, DNA double-strand break repair, Fanconi anemia pathway, alkylating agents, chemoresistance, therapeutic target
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
